+ Filter
Loading...
Custom Services order now ship next day

TNFSF13B

Loading...
Anti-TNFSF13B ProductsTNFSF13BFeatured ProductsCreative Quality ControlCustomer ReviewsrAb ProductionrAb ModalitiesTNFSF13B-Targeted Drug Information

Anti-TNFSF13B Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


At Creative Biolabs, we are dedicated to offering thorough technical assistance for our TNFSF13B recombinant antibody. Our expert team is on hand to help you navigate the complexities of experimental design and fine-tune assay conditions for optimal performance. Whether you need troubleshooting support or data interpretation, our knowledgeable scientists are here to address all your questions about the antibody’s application, storage conditions, and best practices for handling. With a focus on quality and reliability, Creative Biolabs is committed to providing researchers with the highest level of support and enabling these antibodies to make significant contributions to their field.

TNFSF13B: A Promising Target for Autoimmune Diseases

TNF Superfamily Member 13b, commonly referred to as BLys or BAFF, is a crucial element in maintaining the vitality of B cells by interacting with three distinct receptors: BR3, TACI, and BCMA. In clinical scenarios, elevated levels of BLys have been observed in individuals suffering from systemic autoimmune disorders, including rheumatoid arthritis and systemic lupus erythematosus. Research indicates that inhibitors targeting BLys can alleviate disease symptoms and slow down progression in experimental models of these autoimmune conditions. Consequently, BLys represents a promising target for the development of therapeutic agents aimed at treating autoimmune diseases.

Anti-TNFSF13B rAb Products

Our engineered anti-TNFSF13B monoclonal antibodies are designed to effectively target and inhibit TNFSF13B protein, offering high potency and specificity. These versatile antibodies are ideal for research on TNFSF13B’s role in diseases and for exploring potential targeted cancer therapies, with multiple formulations and conjugation options available to meet the diverse experimental requirements.

Table 1. Featured anti-TNFSF13B recombinant antibody products at Creative Biolabs.

Cat. No. Product Name Target Species Host Species Applications
TAB-030 Anti-Human BLys Recombinant Antibody (Belimumab) Human Human IgG1-lambda ELISA, FC, IP, FuncS, IF, Neut, ICC, etc.
HPAB-1257WJ Human Anti-B lymphocyte stimulator protein Recombinant Antibody Human Human IgG ELISA
HPAB-1256WJ Human Anti-B lymphocyte stimulator protein Recombinant Antibody Human Human IgG ELISA
HPAB-1255WJ Human Anti-B lymphocyte stimulator protein Recombinant Antibody Human Human IgG ELISA

Alternative Names

B Lymphocyte Stimulator; B lymphocyte stimulator protein; BAFF; TNF- and APOL-related leukocyte expressed ligand; TALL-1; Dendritic cell-derived TNF-like molecule; CD257 antigen; Cluster of differentiation 257; THANK.

Background

B Lymphocyte Stimulator (BLyS protein) is a member of the tumor necrosis factor (TNF) family of ligands and functions as an essential in vivo regulator of B lymphocyte homeostasis.

Creative Quality Control

Creative Biolabs offers top-tier TNFSF13B recombinant antibody products, designed for exceptional efficacy and reliability. Our rigorous quality control measures ensure each product's excellence for use in immunotherapy and cancer research.

Fig.1 SDS-PAGE analysis. (Creative Biolabs Original)Fig.1 SDS-PAGE analysis of anti-TNFSF13B antibody
(Cat# TAB-030, Creative Biolabs).

Fig.2 HPLC analysis. (Creative Biolabs Original)Fig.2 HPLC analysis of anti-TNFSF13B antibody
(Cat# TAB-030, Creative Biolabs).

Customer Reviews

Excellent
Ba***r
Human Anti-B lymphocyte stimulator protein Recombinant Antibody (HPAB-1257WJ) (HPAB-1257WJ)
The TNFSF13B antibody from Creative Biolabs has consistently delivered reliable and efficient results in my experiments. Its high quality has enabled me to achieve accurate and reproducible outcomes, making it a valuable addition to my research toolkit.
15/Aug/2022
Excellent
Ke***n
Human Anti-B lymphocyte stimulator protein Recombinant Antibody (HPAB-1255WJ) (HPAB-1255WJ)
I recently purchased the TNFSF13B antibody for use in an ELISA assay, and I couldn’t be more satisfied with the results. The antibody demonstrated exceptional specificity and sensitivity, which allowed me to achieve precise and reproducible data in my experiments. Its high quality contributed significantly to the success of my research, providing clear and dependable results every time. Definitely worth recommending!
3/Nov/2023

Anti-TNFSF13B rAb Production

Our anti-TNFSF13B recombinant antibody production platform utilizes genetically engineered cells to express and secrete antibodies targeting the TNFSF13B protein, allowing for scalable and cost-effective antibody production.

Featured Anti-TNFSF13B Recombinant Antibody Production PlatformsFig.3 Milligram-scale. (Creative Biolabs Original)
Fig.3 Milligram-scale anti-TNFSF13B recombinant antibody production.

Fig.4 Gram-scale. (Creative Biolabs Original)Fig.4 Gram-scale anti-TNFSF13B recombinant antibody production.

Anti-TNFSF13B Recombinant Antibody Modalities

Creative Biolabs specializes in providing researchers with innovative and premium-quality anti-TNFSF13B recombinant antibodies in various formats to support their scientific endeavors.

Fig.5 BLyS antibody production and modalities. (Creative Biolabs Original)Fig.5 Full-length anti-TNFSF13B recombinant antibody production and modalities.

TNFSF13B-Targeted Drug Information

Table 2. Public drug targeting TNFSF13B.

Highest Phase Mechanism of Action Product Category Condition Organization
Launched - 2021 Drugs Targeting Tumor Necrosis Factor Ligand Superfamily Member 13 (TNFSF13; APRIL)
Drugs Targeting Tumor Necrosis Factor Ligand Superfamily Member 13B (TNFSF13B; BLyS)
Fc Fusion Proteins
Polypeptides, from 41 AA
Antiphospholipid syndrome
Autoimmune disease
IgA nephropathy
Multiple sclerosis
Myasthenia gravis
Nephritis, lupus
Neuromyelitis optica
Rheumatoid arthritis
Sjogren syndrome
Systemic lupus erythematosus
Peking Union Medical College Hospital (Originator)
RemeGen (Originator)
Tongji University (Originator)
Phase I/II Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Third-Generation CAR)
Multiple myeloma Autolus (Originator)
UCL Business (UCLB) (Originator)
Phase I Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Signal Transduction Modulators
Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells)
Lymphoma, mantle cell
Multiple myeloma
Non-Hodgkin lymphoma
Sjogren syndrome
Case Western Reserve University (Originator)
Luminary Therapeutics (Originator)
Preclinical Anti-CLEC4C (C-Type Lectin Domain Family 4 Member C; BDCA2)
Drugs Targeting Tumor Necrosis Factor Ligand Superfamily Member 13 (TNFSF13; APRIL)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Fusion Proteins
Humanized Monoclonal Antibodies
Polypeptides, from 41 AA
Autoimmune disease Nanjing Leads Biolabs (Originator)
Preclinical Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Signal Transduction Modulators
Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Multiple myeloma Harvard Medical School (Originator)
Massachusetts General Hospital (Originator)
Preclinical Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Signal Transduction Modulators
Cancer Immunotherapy
Cell-Based Gene Therapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Fourth-Generation CAR)
IL-2
Multiple myeloma Elpis Biopharmaceuticals (Originator)
Preclinical Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Cancer Immunotherapy
Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR)
Cancer Case Western Reserve University (Originator)
Preclinical Anti-CD269 (Anti-BCMA)
Anti-TNFRSF13B (TACI; Tumor Necrosis Factor Receptor Superfamily Member 13B)
Signal Transduction Modulators
Bispecific Antibodies
Cancer Immunotherapy
Humanized Monoclonal Antibodies
Multiple myeloma Hummingbird Bioscience (Originator)
Biological Testing Anti-ALB (Human Serum Albumin)
Anti-CD3 (T-Cell Surface Glycoprotein CD3)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13B (TNFRSF13B, TACI)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 13C (TNFRSF13C; CD268; BAFF-R)
Drugs Targeting Tumor Necrosis Factor Receptor Superfamily Member 17 (TNFRSF17, BCMA, CD269)
Signal Transduction Modulators
T-Cell Engagers
Antibody-Derived Binding Proteins
Cancer Immunotherapy
Fusion Proteins
Immunoconjugates
Multispecific Antibodies
Polypeptides, from 41 AA
Acute lymphocytic leukemia
Lymphoma, Burkitt
Multiple myeloma
Peking Univ Shenzhen Graduate School (Originator)
Biological Testing Anti-CD3 (T-Cell Surface Glycoprotein CD3)
Anti-TNFRSF13B (TACI; Tumor Necrosis Factor Receptor Superfamily Member 13B)
Signal Transduction Modulators
Bispecific Antibodies
Cancer Immunotherapy
Multiple myeloma Agency for Science, Technol and Res (Originator)

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Creative Biolabs' anti-TNFSF13B recombinant antibodies are available in various formats, including monoclonal and polyclonal antibodies, and we offer custom options to meet your unique requirements. For your diverse application needs, our comprehensive product line is tailored to support and advance your research endeavor. Get in touch with us to find out how we can help with your scientific needs.

Go to compare

Go to compare